Evelo Biosciences, Inc. announced its strategic priorities and anticipated milestones for 2021. In 2021, Evelo plans to focus on: Advancing EDP1815, its lead anti-inflammatory product candidate, through Phase 2 dose-ranging trials, as well as formulation and manufacturing optimization, towards potential Phase 3 trials in mild to moderate psoriasis and atopic dermatitis. Psoriasis is a chronic skin disease impacting up to 3% of people globally. Atopic dermatitis is the most common chronic skin disease, impacting an estimated 10% of adults and 25% of children globally. Monoclonal antibodies and JAK inhibitors are not typically used in mild to moderate patients, leaving significant unmet need. Expanding the international reach of EDP1815 in hospitalized patients with COVID-19. The TACTIC-E trial recently received regulatory approval in Mexico, adding 7 hospitals to the trial. Generating initial clinical data on the safety and pharmacology of the Company’s next anti-inflammatory product candidate, EDP1867, in atopic dermatitis. Progressing its first extracellular vesicle (EV) candidates EDP2939 for inflammatory diseases and EDP1908 for oncology into first-in-human studies in 2022; andExpanding its discovery and development pipeline into new areas within inflammatory diseases, as well as exploring opportunities beyond its initial therapeutic focus areas of inflammatory diseases and oncology.